Clinical trials: Hepatic Neoplasms
Hepatocellular Carcinoma (HCC)
Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection
This is a multi-center, randomized, open-label pivotal phase II study to evaluate the efficacy and safety of EAL as adjuvant therapy in preventing recurrence in patients with primary HCC at high recurrence risk after radical…
- Trial name
- NCT05213637
- Testing
- Expanded Activated Lymphocytes (EAL), transarterial chemoembolization (TACE)
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Chinese PLA General Hospital
Advanced Hepatocellular Carcinoma
Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma
This is a prospective, single-arm, phase Ib/II trial . The objective of this study is to evaluate the efficacy and safety of adebrelimab, camrelizumab plus apatinib as first-line therapy in patients with advanced hepatocellular…
- Trial name
- NCT05924997
- Testing
- adebrelimab, camrelizumab plus apatinib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma (HCC)
A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data
The system assesses the heterogeneity of HCC patients in terms of therapeutic outcomes (such as rwPFS, ORR, PRO) and adverse reactions during the process of interventional therapy combined with systemic treatment.
- Trial name
- NCT07156617
- Testing
- Interventional therapy, Systemic therapy
- Where
- 14 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Xuhua Duan
Hepatocellular Carcinoma
Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation
Percutaneous ablation (PA) is the only non-surgical curative treatment of hepatocellular carcinoma (HCC). Due to its excellent tolerance, particularly in patients with portal hypertension or bearing comorbidities, it now…
- Trial name
- NIVOLEP (NCT03630640)
- Testing
- Nivolumab Injection [Opdivo]
- Where
- France
- Volunteers
- 43 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. TBI 302 is being developed for the treatment of inoperable HCC by intravenous infusion.
- Trial name
- NCT03908840
- Testing
- TBI 302
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Evolve Biologics
HCC - Hepatocellular Carcinoma, Cholangiocarcinoma Cancer
Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study
The goal of this observational study is to learn what are the best conditions that will give a positive outcome to men and women that receive a intra arterial therapy (IAT) for primary liver cancer.
- Trial name
- NCT06774690
- Where
- Italy
- Volunteers
- 3,300 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
This phase II trial tests whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by…
- Conditions
- Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT05168163
- Testing
- Atezolizumab, Cabozantinib, Lenvatinib
- Where
- 16 sites in United States
- Volunteers
- 122 people
- Sponsor
- Academic and Community Cancer Research United
Advanced Hepatocellular Carcinoma, Atezolizumab
dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma
This study intends to evaluate the efficacy and safety of drug-eluting transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (dTACE-HAIC) plus Bevacizumab and…
- Conditions
- Advanced Hepatocellular Carcinoma, Atezolizumab, Bevacizumab, Chemotherapy
- Trial name
- NCT06609863
- Testing
- dTACE-HAIC
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.
Surgical resection of the affected liver offers the best chance for disease-free survival in patients with Hepatoma (HCC). Unfortunately, most hepatoma patients present with disease which is multi-focal and thus not resectable.
- Trial name
- NCT00152087
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Joseph's Hospital, Florida
Liver Metastasis, Liver Tumors
Radioactive Holmium Microspheres for the Treatment of Liver Metastases
The HEPAR study is aimed at determining the safety of radioactive holmium containing microspheres for the treatment of tumors in the liver.
- Trial name
- HEPAR (NCT01031784)
- Testing
- holmium-166 poly lactic acid microspheres, holmium 166 microspheres
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- UMC Utrecht
Liver Cancer
Gene Therapy in Treating Patients With Cancer of The Liver
Phase I trial to study the effectiveness of gene therapy with the p53 gene in treating patients who have cancer of the liver that cannot be surgically removed.
- Trial name
- NCT00003147
- Testing
- Ad5CMV-p53 gene
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Liver Neoplasms, Hepatobiliary Diseases
Outcomes After Liver and Biliary Resection at a High-Volume Center
The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and/or biliary resection for benign and malignant diseases.
- Conditions
- Liver Neoplasms, Hepatobiliary Diseases, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- BILIVER (NCT07556835)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda USL Toscana Centro
Liver Cancer
Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00077389
- Testing
- carboplatin, cisplatin, doxorubicin hydrochloride
- Where
- 24 sites in France, Ireland and 2 more
- Volunteers
- 57 people
- Sponsor
- University of Leicester
Liver Cancer
A Retrospective Review of Malignant Liver Tumors
This study will review the treatment and outcomes of patients having primary and metastatic hepatic malignancies. Patients treated with surgical resection, percutaneous radiofrequency ablation (RFA), and transarterial…
- Trial name
- NCT00728650
- Where
- United States
- Volunteers
- 228 people
- Sponsor
- University of Oklahoma
HBV, Fibrosis, Liver
Chronic Hepatitis B Virus Infection in Zambia
Chronic hepatitis B virus infection is a common condition in Zambia. Among Zambian blood donors, up to 8% are chronically infected with HBV.
- Conditions
- HBV, Fibrosis, Liver, Cirrhosis, Liver, Alcoholic Hepatitis
- Trial name
- HUTCH (NCT03158818)
- Testing
- Standard of care
- Where
- Zambia
- Volunteers
- 326 people
- Sponsor
- University of Alabama at Birmingham
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Liver Cancer, Hepatocellular Carcinoma
Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of mRNA vaccine for HBV-positive Advanced Hepatocellular Carcinoma.
- Trial name
- NCT05738447
- Testing
- HBV mRNA vaccine
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Liver Cancer, Colorectal Cancer
The Inflammatory Response to Stress and Angiogenesis in Liver Resection
Patients with resectable liver metastases of colorectal origin will be assigned to laparoscopic liver resection or conventional open liver surgery. Blood samples will be drawn preoperatively and 24 hours after resection.
- Conditions
- Liver Cancer, Colorectal Cancer, Metastatic Cancer, Liver Metastases
- Trial name
- NCT03131778
- Testing
- Liver resection
- Volunteers
- 40 people
- Sponsor
- University Hospital, Ghent
Liver Cancer, Adult, Metastatic Liver Cancers
Mts105 for Advanced Hepatocellular Carcinoma
This is the first-in-human trial of MTS105 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS105 in advanced hepatocellular carcinoma.
- Conditions
- Liver Cancer, Adult, Metastatic Liver Cancers, HCC - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
- Trial name
- MTS105 for HCC (NCT06689540)
- Testing
- MTS105
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Shen Lin
HER2-amplified Biliary Tract Cancers
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
This multicenter, open-label, single-arm trial will evaluate the anti-tumor activity of ZW25 (zanidatamab) monotherapy in subjects with human epidermal growth factor receptor 2 (HER2)-amplified, inoperable and advanced or…
- Trial name
- HERIZON-BTC-01 (NCT04466891)
- Testing
- ZW25 (Zanidatamab)
- Where
- 67 sites in United States, Canada and 7 more
- Volunteers
- 87 people
- Sponsor
- Jazz Pharmaceuticals